Clinical Trial Search

Primary: Changes in Serum Il6 Levels Over the 48 Hours Following Achievement of the Thermal Target — 12389; 8859 pg/mL*h — p=0.55

Primary: Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) — 0 percentage of participants

Primary: The Percentage of Patients With Local Regional Recurrence (LRR) of Disease — 2; 3 percentage of participants

Primary: % of Patient Risky Drinking Days — 27.53; 18.58; 15.44; 28.12 percentage of high-risk drinking days

Primary: Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26) — 0.07; -0.19; 0.34 Grams per deciliter (g/dL)

Primary: Log Signal Intensity of Bisphenol A (BPA) in Child Urine Samples — 0.00; 5.43 Log(Arbitrary Units)

Primary: Subject Comfort — 2.6; 4.0 score on a scale — p=<0.0001

Primary: Conditional Weight Gain Difference Between Study Groups — 0.27; -0.12 Conditional Weight Gain score

Primary: Connor Davidson Resilience Scale (CDRISC) — 22.59; 23.53 score on a scale — p=.029

Primary: Non-elective Hospital Admissions — 2; 3; 31; 104 Participants

Primary: Change in Muscle Mass Using Dual X-ray Absorptiometry (DXA) — -183.00; 1434.00 grams

Primary: Incidence of Dose-limiting Toxicity (DLT) of Pembrolizumab and Trametinib Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0…

Primary: Safety of the Zeltiq Device — 7; 4; 12 device/procedure related AEs

Primary: Pain Rating Scores Made on a Visual Analog Scale (VAS) — 0.136; 0.190; 0.126; 0.160 Score on a scale — p=<0.001

Primary: Demonstrated Skill Score in Communication Skills. — 72.02; 79.33; 78.71; 74.65 score on a scale — p=<.001